Q-omics provides the consensus-scored TLR10 profile across patient tissues and cancer cell-line models. TLR10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TLR10 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TLR10 RNA expression shows 18,963 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where TLR10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLR10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLR10 survival associations across molecular data types. TLR10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLR10 RNA expression–survival associations across cancer types. High TLR10 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SKCM, LUAD, CESC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TLR10 RNA expression.
This table summarizes TLR10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TLR10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLR10 shows lower tumor expression in COAD, BLCA, BRCA and UCEC and higher tumor expression in KIRC and LUAD. The KIRC box plot shows higher TLR10 RNA expression in tumor versus normal tissue (log2 FC = +0.950, t-test p < 0.001).
This table shows molecular features associated with TLR10 in patient tissues and cancer cell lines. In patient samples, TLR10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TLR10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
